Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 36249 | 17.94 |
09:34 ET | 3839 | 18.02 |
09:36 ET | 7048 | 18.02 |
09:38 ET | 14107 | 18.089 |
09:39 ET | 2419 | 18.12 |
09:41 ET | 7323 | 18.17 |
09:43 ET | 3409 | 18.106 |
09:45 ET | 2336 | 18.1999 |
09:48 ET | 1608 | 18.12 |
09:50 ET | 2463 | 18.04 |
09:52 ET | 11394 | 18.07 |
09:54 ET | 1000 | 18.09 |
09:56 ET | 800 | 18.12 |
09:57 ET | 2534 | 18.1 |
09:59 ET | 800 | 18.02 |
10:01 ET | 26513 | 17.94 |
10:03 ET | 32036 | 18.03 |
10:06 ET | 20786 | 17.99 |
10:08 ET | 4722 | 17.95 |
10:10 ET | 3346 | 17.935 |
10:12 ET | 6177 | 17.91 |
10:14 ET | 17876 | 17.99 |
10:15 ET | 8677 | 17.9796 |
10:17 ET | 10700 | 17.93 |
10:19 ET | 3535 | 17.9441 |
10:21 ET | 3092 | 18 |
10:24 ET | 5476 | 17.96 |
10:26 ET | 3064 | 17.985 |
10:28 ET | 3053 | 18 |
10:30 ET | 2040 | 17.995 |
10:32 ET | 1915 | 17.995 |
10:33 ET | 1100 | 17.98 |
10:35 ET | 2100 | 17.96 |
10:37 ET | 3754 | 18.01 |
10:39 ET | 700 | 18.01 |
10:42 ET | 1507 | 18.03 |
10:44 ET | 4278 | 18 |
10:46 ET | 1693 | 17.99 |
10:48 ET | 3900 | 17.97 |
10:50 ET | 7456 | 17.96 |
10:51 ET | 7111 | 17.96 |
10:53 ET | 10426 | 18 |
10:55 ET | 1496 | 18.03 |
10:57 ET | 4555 | 18.06 |
11:00 ET | 2613 | 18.06 |
11:02 ET | 643 | 18.05 |
11:04 ET | 4113 | 18.01 |
11:06 ET | 5714 | 17.965 |
11:08 ET | 3903 | 17.96 |
11:09 ET | 4284 | 17.96 |
11:11 ET | 10453 | 17.97 |
11:13 ET | 16920 | 18 |
11:15 ET | 1842 | 17.99 |
11:18 ET | 4310 | 17.98 |
11:20 ET | 1104 | 17.98 |
11:22 ET | 754 | 17.975 |
11:24 ET | 2500 | 17.97 |
11:26 ET | 5807 | 17.96 |
11:27 ET | 7227 | 17.98 |
11:29 ET | 1016 | 17.98 |
11:31 ET | 2149 | 17.98 |
11:33 ET | 1400 | 17.98 |
11:36 ET | 3415 | 17.945 |
11:38 ET | 14017 | 17.98 |
11:40 ET | 11527 | 17.97 |
11:42 ET | 1787 | 17.95 |
11:44 ET | 2315 | 17.96 |
11:45 ET | 958 | 17.94 |
11:47 ET | 2000 | 17.93 |
11:49 ET | 200 | 17.93 |
11:51 ET | 24038 | 18 |
11:54 ET | 4481 | 17.97 |
11:56 ET | 2245 | 17.95 |
11:58 ET | 1983 | 17.94 |
12:00 ET | 13980 | 17.98 |
12:02 ET | 16408 | 17.97 |
12:03 ET | 2873 | 18 |
12:05 ET | 11232 | 18.03 |
12:07 ET | 4620 | 17.99 |
12:09 ET | 11027 | 18.01 |
12:12 ET | 100 | 18 |
12:14 ET | 2087 | 18 |
12:16 ET | 5932 | 17.95 |
12:18 ET | 11975 | 17.99 |
12:20 ET | 16303 | 18 |
12:21 ET | 1278 | 17.99 |
12:23 ET | 2198 | 17.98 |
12:25 ET | 1498 | 18 |
12:27 ET | 1130 | 17.99 |
12:30 ET | 1613 | 17.99 |
12:32 ET | 847 | 18 |
12:34 ET | 6622 | 17.99 |
12:36 ET | 2850 | 17.96 |
12:38 ET | 1406 | 17.95 |
12:39 ET | 18528 | 17.95 |
12:41 ET | 30813 | 17.93 |
12:43 ET | 13868 | 17.945 |
12:45 ET | 8516 | 18.005 |
12:48 ET | 3200 | 18 |
12:50 ET | 3862 | 17.97 |
12:52 ET | 547 | 17.955 |
12:54 ET | 2490 | 17.945 |
12:56 ET | 9288 | 17.96 |
12:57 ET | 21468 | 17.9475 |
12:59 ET | 4234 | 17.93 |
01:01 ET | 24622 | 17.98 |
01:03 ET | 4993 | 17.97 |
01:06 ET | 3331 | 17.97 |
01:08 ET | 5376 | 18 |
01:10 ET | 1293 | 18.005 |
01:12 ET | 6780 | 18.03 |
01:14 ET | 4074 | 18.06 |
01:15 ET | 10388 | 18.09 |
01:17 ET | 6346 | 18.07 |
01:19 ET | 400 | 18.08 |
01:21 ET | 2500 | 18.07 |
01:24 ET | 2175 | 18.08 |
01:26 ET | 3881 | 18.03 |
01:28 ET | 6040 | 17.99 |
01:30 ET | 3799 | 17.96 |
01:32 ET | 12553 | 18.0137 |
01:33 ET | 1386 | 17.99 |
01:35 ET | 2483 | 17.99 |
01:37 ET | 6964 | 18.02 |
01:39 ET | 4176 | 18.07 |
01:42 ET | 3262 | 18.07 |
01:44 ET | 2683 | 18.025 |
01:46 ET | 3849 | 18.05 |
01:48 ET | 200 | 18.03 |
01:50 ET | 3555 | 18.01 |
01:51 ET | 3207 | 18.0319 |
01:53 ET | 1540 | 18.03 |
01:55 ET | 1519 | 18.045 |
01:57 ET | 3359 | 18.07 |
02:00 ET | 200 | 18.07 |
02:02 ET | 4432 | 18.11 |
02:04 ET | 4781 | 18.155 |
02:06 ET | 2372 | 18.16 |
02:08 ET | 10654 | 18.21 |
02:09 ET | 9789 | 18.2 |
02:11 ET | 200 | 18.19 |
02:13 ET | 1770 | 18.22 |
02:15 ET | 7573 | 18.251 |
02:18 ET | 1257 | 18.235 |
02:20 ET | 2299 | 18.24 |
02:22 ET | 7100 | 18.23 |
02:24 ET | 5540 | 18.225 |
02:26 ET | 2454 | 18.24 |
02:27 ET | 600 | 18.245 |
02:29 ET | 12992 | 18.24 |
02:31 ET | 1112 | 18.25 |
02:33 ET | 4646 | 18.275 |
02:36 ET | 1700 | 18.3 |
02:38 ET | 2100 | 18.31 |
02:40 ET | 5080 | 18.345 |
02:42 ET | 20362 | 18.415 |
02:44 ET | 44076 | 18.45 |
02:45 ET | 8757 | 18.415 |
02:47 ET | 600 | 18.41 |
02:49 ET | 2593 | 18.42 |
02:51 ET | 7192 | 18.41 |
02:54 ET | 1044 | 18.395 |
02:56 ET | 3755 | 18.4 |
02:58 ET | 520 | 18.4 |
03:00 ET | 5097 | 18.39 |
03:02 ET | 2924 | 18.4 |
03:03 ET | 3203 | 18.415 |
03:05 ET | 1700 | 18.392 |
03:07 ET | 2100 | 18.395 |
03:09 ET | 1700 | 18.405 |
03:12 ET | 2276 | 18.37 |
03:14 ET | 2319 | 18.38 |
03:16 ET | 1034 | 18.385 |
03:18 ET | 13696 | 18.4199 |
03:20 ET | 5163 | 18.395 |
03:21 ET | 1400 | 18.4 |
03:23 ET | 1404 | 18.39 |
03:25 ET | 2355 | 18.385 |
03:27 ET | 5600 | 18.39 |
03:30 ET | 7500 | 18.43 |
03:32 ET | 2742 | 18.36 |
03:34 ET | 4723 | 18.355 |
03:36 ET | 20092 | 18.34 |
03:38 ET | 17629 | 18.25 |
03:39 ET | 3926 | 18.2437 |
03:41 ET | 6184 | 18.36 |
03:43 ET | 11335 | 18.35 |
03:45 ET | 10861 | 18.3761 |
03:48 ET | 6098 | 18.365 |
03:50 ET | 12283 | 18.335 |
03:52 ET | 11226 | 18.31 |
03:54 ET | 18881 | 18.3201 |
03:56 ET | 22939 | 18.275 |
03:57 ET | 22683 | 18.3 |
03:59 ET | 257261 | 18.31 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 2.8B | 83.0x | --- |
Twist Bioscience Corp | 2.8B | -14.1x | --- |
Arrowhead Pharmaceuticals Inc | 3.1B | -6.0x | --- |
ADMA Biologics Inc | 2.6B | -558.8x | --- |
MorphoSys AG | 2.7B | -5.4x | --- |
Arcellx Inc | 2.8B | -51.3x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8B |
---|---|
Revenue (TTM) | $289.3M |
Shares Outstanding | 154.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.23 |
EPS | $0.22 |
Book Value | $1.06 |
P/E Ratio | 83.0x |
Price/Sales (TTM) | 9.8 |
Price/Cash Flow (TTM) | 68.4x |
Operating Margin | 16.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.